A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

Phase 2

Completed

• Conditions: Male Pattern Baldness; Androgenetic Alopecia; Female Pattern Baldness
• Interventions: Biological: Autologous cultured dermal and epidermal cells

• Registration Number: NCT01451151
• Lead Sponsor: Aderans Research Institute

Brief Summary

The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12
• Study First Submitted: 2011-10-11
• Study First Submitted QC: 2011-10-12
• Study First Posted: 2011-10-13
• Primary Completion: 2012-06
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-09
• Last Update Posted: 2013-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Male and female volunteers 18 to 65 years old, inclusive
• Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
• Able to provide informed consent after risks and benefits of the study have been explained.
• Be willing to undergo all study procedures.
• Ability to communicate effectively with study personnel.
• Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
• Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study.

Exclusion Criteria

• Known sensitivity to DMEM/F-12 or any component of the study material.
• Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
• Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
• A history of drug or alcohol abuse within 1 year of study enrollment.
• Paricipation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
• Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
• Clinically significant abnormal laboratory parameters.
• A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
• Clinically significant dermatologic condition in donation or study areas.
• Prior surgery in the donor or study areas.
• Insufficient hair or scarring in the donor area that might impact cell growth.
• Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treated	Autologous cultured dermal and epidermal cells	-

Primary Outcome Measures

Name	Time	Method
Change from baseline in hair number	51 weeks post-injection
Change from baseline in hair width	51 weeks post-injection
Time course of any treatment benefit	51 weeks post-injection

Trial Locations

Locations (1)

Axis Clinical Trials, Inc.; 🇺🇸 New Hyde Park, New York, United States